CEO-Backed Financing Gives ProPhase Labs Costly $1M Cash Infusion

Rhea-AI Filing Summary

ProPhase Labs (Nasdaq: PRPH) filed an 8-K disclosing two identical $500,000 secured loans executed on June 22 2025 with CEO Ted Karkus (a related-party) and an unaffiliated investor.

• 20% original-issue discount; company receives $400k per loan
• 10% annual interest; 12-month maturity; prepayable anytime
• Loans are subordinate to up to $6 million of future senior debt
• Company pays the CEO a $10,000 expense reimbursement
• Issued 500,000 unvested warrants at a $0.60 strike, vesting only after shareholder approval of additional authorized shares

The Audit Committee approved the related-party terms. The warrant issuance relies on Rule 506 of Regulation D. The filing creates a new financial obligation, unregistered equity issuance, and potential dilution, affecting near-term liquidity and governance optics.

Positive

• Secures $1 million in additional liquidity, improving near-term cash position
• Warrants do not vest until shareholder approval, delaying immediate dilution

Negative

• Effective cost of capital exceeds 30 % when combining 20 % OID and 10 % interest
• Issuance of 500,000 warrants at $0.60 introduces potential shareholder dilution
• Related-party loan with CEO raises governance and conflict-of-interest concerns

Insights

Financial Analyst

TL;DR: Costly insider financing boosts cash but signals constrained capital access.

The company secures a quick $1 million lifeline, yet the economics are steep. After the 20 % OID, only $800k reaches cash, while 10 % coupon plus OID implies an effective annualized cost above 30 %. Subordination to $6 million of future debt further weakens lender security, indicating limited leverage capacity. Although the loan is prepayable without penalty, repayment inside 12 months will require either operating cash flow or refinancing on better terms—neither is assured. The 500k warrants priced at $0.60 add dilution risk if shares trade above the strike post-approval. On balance, liquidity improves, but expensive terms and dilution pressure weigh heavily.

Corporate Governance Expert

TL;DR: Related-party loan with attached warrants heightens governance scrutiny.

A CEO-funded loan can align interests, yet this structure raises conflicts. The 20 % discount, 10 % rate, and 500k warrants could be viewed as preferential, even though the Audit Committee signed off. Shareholder approval is still needed for warrant vesting, offering a check on immediate dilution, but investors must vote knowing the same executive benefits. The subordination clause may deter third-party financiers, concentrating influence with insiders. While board oversight and reliance on Reg D provide legal cover, perception risks remain high, especially if alternative financing could have been cheaper. Transparency mitigates but does not eliminate these concerns.

false 0000868278 0000868278 2025-06-26 2025-06-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 26, 2025

PROPHASE LABS, INC.

(Exact name of Company as specified in its charter)

Delaware		000-21617		23-2577138
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

626 RXR Plaza, 6th Floor Uniondale, New York		11556
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (215) 345-0919

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered Pursuant to Section 12(b) of the Exchange Act:

Title of Each Class		Trading Symbol		Name of Each Exchange on Which Registered
Common Stock, par value $0.0005		PRPH		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Material Definitive Agreement.

On June 22, 2025, ProPhase Labs, Inc. (the “Company”) entered into two identical loan agreements (the “Loan Agreements”) with Ted Karkus, the Company’s Chief Executive Officer and the Chairman of the Board of Directors, and a second unaffiliated investor. For Mr. Karkus, the Loan Agreement constitutes a related party transaction under Item 404(a) of Regulation S-K.

The material terms of the loan are a non-convertible loan in the amount of $500,000, with a 20% original issue discount. The loan bears interest at an annual rate of 10% and matures twelve (12) months from the execution date. The Company will pay Mr. Karkus a $10,000 non-accountable expense and legal reimbursement. The loan is secured by the Company but subordinate to other potential lenders up to $6,000,000 and may be prepaid by the Company at any time without penalty. In connection with the Loan Agreement, the Company also issued 500,000 unvested warrants to purchase shares of the Company’s common stock. Such warrants do not vest until a future shareholders’ approval of an increase in the Company’s authorized shares of common stock (the “Unvested Warrants”).  The Unvested Warrants have an exercise price of $0.60.

The terms of the loan were reviewed and approved by the Audit Committee of the Board of Directors in accordance with the Company’s related-party transaction policy.

The foregoing summary of the Loan Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Loan Agreement, a copy of which is attached as Exhibit 10.1 hereto and incorporated herein by reference.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information provided in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

Item 3.02 Unregistered Sales of Equity Securities.

The disclosure under Item 1.01 is incorporated herein by reference. The issuance of the Unvested Warrant was made in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506 of Regulation D promulgated thereunder. The Lender represented to the Company that it is an accredited investor within the meaning of Rule 501 under the Securities Act.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

No.		Description
99.1*		Loan Agreement, dated June 22, 2025, by and between ProPhase Labs, Inc. and Ted Karkus
99.2*		Loan Agreement, dated June 22, 2025, by and between ProPhase Labs, Inc. and unaffiliated investor
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

* To be filed by amendment 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ProPhase Labs, Inc.
	By:	/s/ Ted Karkus
		Ted Karkus
		Chairman of the Board and Chief Executive Officer

Date: June 26, 2025

FAQ

What are the key financial terms of PRPH's June 2025 loans?

Each loan is $500,000 with a 20 % original-issue discount, 10 % annual interest, and a 12-month maturity, prepayable without penalty.

How much net cash will ProPhase Labs receive from the $1 million loans?

After the 20 % discount, the company receives $800,000 in gross proceeds.

How many warrants were issued and at what exercise price?

The company issued 500,000 unvested warrants exercisable at $0.60 per share.

When will the unvested warrants granted to lenders vest?

They vest only after shareholders approve an increase in authorized common shares.

Was the insider loan approved by the board's Audit Committee?

Yes. The Audit Committee reviewed and approved the CEO's loan under the related-party transaction policy.

What securities law exemption covers the warrant issuance?

The issuance relies on Section 4(a)(2) and Rule 506 of Regulation D.